The Global Hepatocellular Carcinoma Market is expected to grow at a high CAGR during the forecasting period (2022-2029).
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is the most common cause of death in people with cirrhosis.
Hepatocellular carcinoma is amongst the most common types of liver malignancy that mostly occurs in people with chronic liver diseases, such as cirrhosis. The increasing prevalence of chronic liver diseases, rising elderly population, and increasing research & development investments are some of the factors leading to the growth of the market.
The incidence of Hepatocellular Carcinoma is majorly in North America, Western Europe, non-Western countries, like sub-Saharan Africa, Central, and Southeast Asia.
HCC mostly occurs in people with cirrhosis of the liver, and so risk factors generally include factors that cause chronic liver disease that may lead to cirrhosis. Still, certain risk factors are much more highly associated with HCC than others.
Since hepatitis B and C are some of the main causes of hepatocellular carcinoma, prevention of infection is key to then prevent HCC. Thus, childhood vaccination against hepatitis B may reduce the risk of liver cancer in the future.
It is most common in males than females between the age of 35 to 60. Globally, HCC causes about 662,000 deaths per year about half of them in China. In 2015, by age. according to the NIAAA, among those aged 55 to 64 years, 13,818 deaths occurred due to liver cirrhosis in 2015.
Market drivers include the availability of novel drugs, a strong pipeline basis, and public presence. Unhealthy lifestyles and a growing geriatric population is the factor that is driving the growth of the liver cancer therapeutics market.
Liver cancer is the fifth most prevalent cancer worldwide.
The liver cancer market pipeline is extremely innovative and distinct. The market offers huge opportunities to develop breakthrough first-in-class therapies due to high undelivered needs.
The United States had the highest market share of HCC, compared to the EU5 countries, Japan and China.
Moreover, clinical advancements blended with the approval of novel drugs by the regulatory agencies for treating hepatocellular carcinoma are augmenting the growth of the market.
Local Ablation Therapy
The chemotherapy segment holds the largest market share by treatment in the global Hepatocellular Carcinoma market. This therapy minimizes the number of cancerous cells in the body, hence, reducing the chances of spreading cancer, especially in the liver. The commonly used drugs used in chemotherapy include STIVARGA, NEXAVAR, Adriamycin, cisplatin, among others.
Cancer rehabilitation centers
The market is segmented geographically into North America, South America, Europe, Asia-Pacific, and the Middle East, and Africa. In 2014, the number of deaths from chronic liver diseases and cirrhosis among men in Spain amounted to approximately three thousand deaths.
The leading players of the global Hepatocellular Carcinoma Cancer market include Novartis AG, Pfizer Inc, Eli Lilly and Company, Bristol-Mayers Squibb, Teva Pharmaceutical Industries Ltd., Bayer AG, Polaris Pharmaceuticals, Inc. (PPI), and others.
The major drugs used for the treatment of HCC include Nexavar, Sorafenib, Regorafenib, Nivolumab, and others.
Some of the recent development in the global Hepatocellular Carcinoma market are:
In Sept 2017, the FDA granted the approval to nivolumab (Opdivo) for the treatment of patients with hepatocellular carcinoma (HCC) following prior sorafenib (Nexavar), regardless of PD-L1 status.
Get your free sample proposal with a single click!